Want to see XWEL full AI Analyst Report?
Top Page
XWELL
(NASDAQ:XWEL)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.90
▼(-9.80% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily held down by weak financial performance—sharp revenue contraction, deep losses, negative equity, and ongoing cash burn. Technicals also lean bearish (negative MACD and trading below key moving averages), offering limited support despite mildly oversold readings. Corporate events provide some offset via a potentially balance-sheet-positive divestiture, but valuation support is limited due to losses (negative P/E) and no dividend.
Positive Factors
Improved Gross Margin
Improved gross margin indicates better unit economics than at the 2023 trough. If sustained, this could support future profitability, although current operating costs remain too high for the improvement to offset ongoing losses.
Negative Factors
Severe Revenue Contraction
The sharp revenue contraction and multi-year pattern of volatile, generally declining sales weaken operating scale and reduce the ability to absorb fixed costs. Without a durable revenue recovery, margin improvements are unlikely to produce sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Margin
Improved gross margin indicates better unit economics than at the 2023 trough. If sustained, this could support future profitability, although current operating costs remain too high for the improvement to offset ongoing losses.
Read all positive factors
XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.38M
Dividend YieldN/A
Average Volume (3M)34.77K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue Growth-7.58%
EPS Growth-30.33%
CountryUS
Employees175
SectorHealthcare
Sector Strength45
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)-5.29
Shares Outstanding8,589,266
10 Day Avg. Volume43,409
30 Day Avg. Volume34,772
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.07
Price to Sales (P/S)0.05
P/FCF Ratio-0.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XWELL Business Overview & Revenue Model
Company Description
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services featu...
How the Company Makes Money
null...
XWELL Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Read all positive updates
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.XWELL Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.28M | 29.21M | 33.90M | 30.11M | 55.94M | 73.73M |
| Gross Profit | 8.68M | 6.64M | 8.92M | 3.68M | 12.05M | 32.34M |
| EBITDA | -21.44M | -14.16M | -11.16M | -15.75M | -19.12M | 8.14M |
| Net Income | -23.42M | -16.99M | -16.85M | -27.74M | -32.84M | 3.35M |
Balance Sheet | ||||||
| Total Assets | 20.53M | 11.22M | 25.35M | 38.99M | 70.43M | 127.27M |
| Cash, Cash Equivalents and Short-Term Investments | 11.78M | 2.62M | 11.80M | 23.05M | 42.19M | 105.51M |
| Total Debt | 7.29M | 12.49M | 10.77M | 11.09M | 14.11M | 13.82M |
| Total Liabilities | 12.27M | 23.80M | 17.61M | 18.02M | 22.48M | 27.33M |
| Stockholders Equity | -1.85M | -22.04M | -788.00K | 13.00M | 39.93M | 92.73M |
Cash Flow | ||||||
| Free Cash Flow | -13.48M | -11.68M | -12.80M | -18.45M | -31.02M | 6.97M |
| Operating Cash Flow | -11.27M | -8.71M | -11.01M | -16.07M | -24.19M | 14.56M |
| Investing Cash Flow | 689.00K | 4.33M | 5.89M | 5.65M | -34.84M | -5.16M |
| Financing Cash Flow | 17.48M | 1.94M | 1.36M | 8.00K | -27.38M | 6.35M |
XWELL Technical Analysis
Neutral
1.00
Price Trends
1.01
Negative
1.14
Negative
0.97
Positive
Market Momentum
-0.02
Negative
48.33
Neutral
24.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Neutral. The current price of 1 is above the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.01, and above the 200-day MA of 0.97, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 24.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 61 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XWELL Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $71.22M | 10.33 | 3.66% | 1.67% | 6.83% | -94.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $141.21M | -5.42 | -12.68% | 8.20% | -34.03% | -801.27% | |
44 Neutral | $8.38M | -0.18 | 317.52% | ― | -7.58% | -30.33% | |
44 Neutral | $7.27M | -1.87 | -68.38% | ― | ― | ― | |
43 Neutral | $4.70M | -0.03 | -375.72% | ― | 197.50% | 99.51% | |
40 Neutral | $3.90M | -0.53 | 1.38% | ― | -1.57% | ― |
* Healthcare Sector Average
XWEL
XWELL
0.98
-0.12
-10.55%
MED
Medifast
12.63
-1.19
-8.61%
RGS
Regis
28.50
2.36
9.05%
MRM
MEDIROM Healthcare Technologies
0.92
-1.02
-52.58%
EJH
E-Home Household Service Holdings
1.22
-26.02
-95.52%
TRNR
Interactive Strength Inc
2.90
-225.30
-98.73%
XWELL Corporate Events
Business Operations and StrategyExecutive/Board Changes
XWELL CEO Steps Off Board, New Director Appointed
Positive
Aug 5, 2026
On August 3, 2026, XWELL, Inc. announced that President and Chief Executive Officer Ezra T. Ernst resigned from the company’s Board of Directors and its committees, while retaining his executive roles. The company said the board resignation ...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
XWELL Divests Airport Businesses to Refocus Strategy
Positive
Jul 9, 2026
On July 6, 2026, XWELL entered into a Securities Purchase Agreement to sell all its equity interests in XpresSpa Holdings, which runs airport spa locations, and XpresTest, which conducts airport bio surveillance testing, to Express Wellness Group,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.